UCB Aktie [WKN DE: A14WZY / ISIN: US9034801012]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu UCB SA Unsponsored American Deposit Receipt Repr 1-2 Sh

02.12.23		UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting (PR Newswire)
01.12.23		UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting (PR Newswire)
14.11.23		UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis (PR Newswire)
11.11.23		Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF) (PR Newswire)
10.11.23		UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023 (PR Newswire)
01.11.23		UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Founda... (PR Newswire)
31.10.23		NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters (PR Newswire)
18.10.23		BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis (PR Newswire)
18.10.23		UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis (PR Newswire)
13.10.23		UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023 (PR Newswire)
12.10.23		Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa (PR Newswire)
21.07.23		UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-mu... (PR Newswire)
27.06.23		UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis (PR Newswire)
20.04.23		UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
17.04.23		UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance (PR Newswire)
18.03.23		Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks (PR Newswire)
16.03.23		UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa (PR Newswire)
18.01.23		Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis (PR Newswire)
06.01.23		UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review (PR Newswire)
09.12.22		UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa (PR Newswire)
07.12.22		The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis (PR Newswire)
01.12.22		UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care (PR Newswire)
23.11.22		Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS) (PR Newswire)
14.11.22		UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients (PR Newswire)
10.11.22		Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis (PR Newswire)
08.11.22		UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022 (PR Newswire)
26.09.22		UCB U.S. HEADQUARTERS IN ATLANTA AWARDED PRESTIGIOUS LEED GOLD AND WELL PLATINUM CERTIFICATIONS (PR Newswire)
22.09.22		UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting (PR Newswire)
07.09.22		New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis (PR Newswire)
01.09.22		UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress (PR Newswire)
23.05.22		First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 (PR Newswire)
23.05.22		UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 (PR Newswire)
10.05.22		UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis (PR Newswire)
02.05.22		JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS) (PR Newswire)
01.04.22		UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
28.03.22		FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) (PR Newswire)
26.03.22		New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting (PR Newswire)
04.02.22		UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results (PR Newswire)
21.01.22		Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study (PR Newswire)
19.01.22		UCB to acquire Zogenix (PR Newswire)
18.01.22		Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study (PR Newswire)
16.12.21		Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial (PR Newswire)
03.12.21		UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care (PR Newswire)
02.12.21		UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease (PR Newswire)
19.11.21		Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms (PR Newswire)
05.11.21		UCB Showcases Key Rheumatology Data at ACR Convergence 2021 (PR Newswire)
03.11.21		Sharecare and UCB to present on future of decentralized clinical research at 2021 CNS Summit (PR Newswire)
27.10.21		Unique Patient-led and Co-authored Analysis of the Experience of Living with Myasthenia Gravis Published in Neurology and Therapy (PR Newswire)
20.10.21		UCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Lab (PR Newswire)
16.10.21		Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer Mobility-Aktie knickt ein: KTM wird Produktionsstopp womöglich verlängern

'Squid Game': Staffel 2 setzt Erfolgsgeschichte auf Netflix fort - Trailer zur dritten Staffel veröffentlicht - Aktie sinkt leicht

Bitcoin, Ether & Co: Die Gewinner und Verlierer der Kryptowährungen 2024

Steinmeier setzt Neuwahlen für 23. Februar an

Crash oder Rally: Das sind die Experten-Prognosen für Kryptowährungen wie Bitcoin, Ethereum & Co. im Jahr 2025

NVIDIA-Aktie in Gefahr? Analyst warnt vor Tech-Aktiencrash in 2025

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	03.01.2025 08:17
Kaufwert:	EUR
	Hinzufügen Speichern